Intervacc AB (fra:2E9) Share Price

Company Profile

Business description
Intervacc AB is a Swedish animal health company that develops, manufactures and commercializes veterinary vaccines based on its proprietary recombinant fusion protein technology platform. Its product, Strangvac, is a vaccine against equine strangles and is marketed across multiple European countries. The company is also developing Piggivac for Streptococcus suis infections in pigs and operates through animal health, veterinary pharmaceuticals and diagnostic services. Geographically, the company generates its revenue from Europe through vaccine sales and distribution partnerships, while expansion targets North America, Australia and New Zealand.
Contact
Vastertorpsvagen 135 B
Hagersten
StockholmS-129 44
SWE
T: +46 812010600
https://www.intervacc.se
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,093.37	158.69	0.69%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%